Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of fremanezumab for preventive treatment of episodic migraine
2015-004598-34Phase 3Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- May 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fremanezumab in episodic migraine and migraine (3 arms), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoint: Mean change from baseline in monthly average number of migraine days. Started May 2016; status: completed.
02
Drugs
fremanezumab
03
Conditions
episodic migrainemigraine
Beyond the preview
Go deeper on 2015-004598-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004598-34.